Movement Alert｜Ionis Pharmaceuticals Rises 5.31% in Regular Trading, Phase 3 Trial for IgA Nephropathy Achieves Primary Endpoint

Market Focus10-10

On October 10, Ionis Pharmaceuticals rose 5.31% in regular trading, reaching $45.60 per share with turnover of $76.08 million. The move was driven by the announcement that sefaxersen, its investigational therapy co-developed with Roche, met the primary endpoint in a pivotal Phase 3 study for adults with primary IgA nephropathy.

At week 37, sefaxersen demonstrated a statistically significant and clinically meaningful reduction in proteinuria compared to placebo, with a safety profile consistent with prior studies. The trial will continue to evaluate kidney function changes over two years, measured by estimated glomerular filtration rate at week 105. This news strengthens the outlook for Ionis' RNA-targeted pipeline, coming just one week after its ALS candidate ulefnersen also achieved its Phase 3 primary endpoint.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment